Role of Capsule and O Antigen in the Virulence of Uropathogenic Escherichia coli

Sohinee Sarkar, Glen C. Ulett, Makrina Totsika, Minh-Duy Phan, Mark A. Schembri

Abstract

Urinary tract infection (UTI) is one of the most common bacterial infections in humans, with uropathogenic Escherichia coli (UPEC) the leading causative organism. UPEC has a number of virulence factors that enable it to overcome host defenses within the urinary tract and establish infection. The O antigen and the capsular polysaccharide are two such factors that provide a survival advantage to UPEC. Here we describe the application of the rpsL counter selection system to construct capsule (kpsD) and O antigen (waaL) mutants and complemented derivatives of three reference UPEC strains: CFT073 (O6:K2:H1), RS218 (O18:K1:H7) and 1177 (O1:K1:H7). We observed that while the O1, O6 and O18 antigens were required for survival in human serum, the role of the capsule was less clear and linked to O antigen type. In contrast, both the K1 and K2 capsular antigens provided a survival advantage to UPEC in whole blood. In the mouse urinary tract, mutation of the O6 antigen significantly attenuated CFT073 bladder colonization. Overall, this study contrasts the role of capsule and O antigen in three common UPEC serotypes using defined mutant and complemented strains. The combined mutagenesis-complementation strategy can be applied to study other virulence factors with complex functions both in vitro and in vivo.

Introduction

Urinary tract infections (UTIs) are one of the most common types of bacterial infection in humans. Approximately 150 million cases of UTI are estimated to occur around the globe annually [1]. UTI occurs frequently in women; it is estimated that 40–50% of adult healthy women experience at least one UTI episode in their lifetime [2]. Catheterized patients, the elderly and children are also at a higher risk for UTI [3–5]. If untreated, UTI may progress from the bladder to the kidneys and even cause life-threatening urosepsis. The estimated annual cost of treating UTI in the USA alone is greater than $1.6 billion, thus emphasizing the global economic burden these infections place on health care systems [2].

Uropathogenic Escherichia coli (UPEC) is the primary causative organism in more than 80% of all UTI cases [6]. UPEC isolates exhibit a high degree of genetic diversity, primarily due to the possession of specialized virulence genes located on mobile genetic elements called pathogenicity islands [7,8]. Although no single virulence factor is uniquely definitive of UPEC, their ability to cause symptomatic UTI is enhanced by adhesins (e.g. type 1, and P fimbriae), toxins (e.g. hemolysin), iron acquisition systems and cell surface polysaccharides [9–11]. The capsule and the O antigen represent two cell-surface associated polysaccharides that contribute to UPEC virulence [12–14]. These extracellular polysaccharides protect UPEC against phagocytosis by immune cells such as neutrophils and inhibit complement-mediated killing [15,16]. Bacterial lipopolysaccharide (LPS) plays a primary role in mediating UPEC resistance to the bactericidal activity of human serum [17]. LPS consists of the highly conserved lipid A-core and repeating O antigen subunits that differ greatly between strains based on the sugar residues and their linkage patterns within the repeating subunits [18]. More than 180 different serotypes have been reported for E. coli [18,19], with some O antigen types such as O1, O2, O4, O6, O7, O8, O16, O18, O25, and O75 being common among UPEC strains [20]. This variation is imparted by differences in the genes that encode for glycosyltransferase enzymes that modify O antigen structure. The lipid A-core and the O antigen subunits are assembled in separate pathways that come together for ligation at the inner membrane [21]. WaaL is a conserved O antigen ligase and the only known membrane enzyme implicated in the ligation of pre-assembled undecaprenyl-diphosphate [Und-PP]-linked O antigen to lipid A-core oligosaccharide [22]. E. coli K-12 waaL deletion mutants are unable to cap the lipid A-core and are therefore disrupted in the expression of O antigen at the cell surface [23].

Like the O antigen, there is also significant variation in the E. coli capsule. More than 80 distinct types of E. coli capsule have been identified, with four major groups defined based on genetic assembly, biochemistry and physical attributes [24]. The group 2 capsular polysaccharides have mostly been associated with UPEC strains [12,25]. The role of the capsule in protecting UPEC from phagocytosis has been defined [26,27], however, its role in resistance to serum-mediated killing is unclear, with several
conflicting reports in the literature [28–31]. Understanding the role of the capsule in UPEC serum resistance is further complicated by the use of multiple strains with different O antigen and capsule types. For example, a multi-strain study by Stawski et al. found that the contribution of capsule to serum resistance varied between strains and ranged from being important to having no protective role [32]. The genes involved in capsule production are located in the **kps**UDUCS operon [24,33]. **KpsD** is a 50 kDa outer membrane protein involved in the export of group 2 capsular polysaccharides across the outer membrane [34]. Mutation of **kpsD** results in the loss of surface expression of the capsule and accumulation of polysaccharide within the periplasmic space [35].

Given the importance of O antigen and capsule in UPEC virulence, we studied the function of these polysaccharides in three well-characterized UPEC strains (CFT073, RS218 and 1177) bearing different O and K antigens. We employed a recently described counter-selection strategy based on streptomycin-kanamycin resistance (mediated by the **rpsL** and **neo** genes, respectively) for the mutation of single genes and the subsequent repair of these mutations to generate complemented strains [36]. This enabled us to generate a defined set of wild-type (WT), mutant and complemented strains that were used to test the contributions of O antigen and capsule to UPEC virulence. Our study is the first to demonstrate the use of the **rpsL-neo** counter-selection system in UPEC, and shows that the O antigen is the major polysaccharide responsible for UPEC serum resistance and survival in the mouse urinary tract.

**Results**

**Construction of capsule and O antigen insertion mutants**

A prerequisite for the **rpsL-neo** counter-selection system is that the bacterial strain should be streptomycin resistant (**Strep**R) and that this resistance is the direct effect of a mutation within the **rpsL** gene. Streptomycin resistance is a recessive trait and in the presence of both WT and mutant alleles, the strain is sensitive to streptomycin (**Strep**T) [37]. This trait can be exploited for the rapid mutation and repair of mutated genes, and a schematic outline of the strategy we employed is presented in Figure 1. **Strep**R derivatives of the UPEC strains CFT073 (O6:K2), 1177 (O1:K1) and RS218 (O18:K1) were generated sequentially by spontaneous plating on increasing concentrations of streptomycin. These **Strep**R strains (CFT073**rpsL**(Strep, 1177**rpsL**(Strep, RS218**rpsL**(Strep)) were then transformed with pRedET, a temperature sensitive expression counter-selection system in E. coli [35].

**KpsD** gene reverted them to a **Strep**R phenotype. The **Strep**R derivatives of the UPEC strains CFT073 (O6:K2), 1177 (O1:K1) and RS218 (O18:K1) were generated sequentially by spontaneous plating on increasing concentrations of streptomycin. These **Strep**R strains (CFT073**rpsL**(Strep, 1177**rpsL**(Strep, RS218**rpsL**(Strep)) were then transformed with pRedET, a temperature sensitive expression counter-selection system in E. coli [35].

**Phe**

**Lytic characterization of capsule mutants and complements**

The **K1** phage assay was used to detect the presence of a **K1** capsule on the surface of UPEC strains 1177 and RS218 (Figure 2). In this assay, the 1177 and RS218 WT strains were killed upon encountering the phage due to its specific attachment to the **K1** capsule and subsequent lytic replication life-cycle. In contrast, the **kpsD** mutants exhibited normal growth beyond the streak line, indicating a loss of **K1** capsule expression and thus resistance to phage killing. A WT phenotype was fully restored in the complemented strains. In separate experiments, counter-current immunoelectrophoresis using **K2** antiserum was used to detect **K2** capsule on the surface of CFT073. Capsular extracts from CFT073, CFT073**kpsD** and CFT073**kpsD** were electrophoresed against **K2** antisera. A precipitin band was observed for CFT073 and CFT073**kpsD**, while this was absent in CFT073**kpsD**. Taken together, these results confirm the **K1** or **K2** capsule phenotype of the three mutated and complemented UPEC strains.

**Phenotypic characterization of O antigen mutants and complements**

The **waaL** gene encodes an O antigen ligase and its mutation abolishes the attachment of the O antigen to the LPS core, resulting in a rough phenotype. In order to phenotype characterize the **waaL** mutants and their complemented strains, LPS extracts were prepared from standardized late log phase cultures, separated by TSDS-PAGE and viewed by silver staining (Figure 3). As expected, due to their different O types, the LPS banding patterns from WT CFT073, 1177 and RS218 varied. E. coli 1177 (O1) possessed an even distribution of short, medium and long O antigen side chains, while CFT073 (O6) and RS218 (O18) possessed predominantly short and long O antigen side chains. Disruption of the **waaL** gene resulted in complete loss of the bands corresponding to the O antigen subunits from all strains, with only the lipid A-core detected. In each of the complemented strains, the O antigen-bandung profile was restored to WT.

**O antigen is the major determinant of serum resistance**

To compare the relative contribution of O antigen and capsule to UPEC serum resistance we tested our WT, mutant and complemented strains in a serum survival assay. In this assay, bacterial survival was measured as colony forming units (CFU) before and after incubation with pooled normal human sera. As expected, the WT strains CFT073, 1177 and RS218 were resistant to killing by human serum (Figure 4). In contrast, the CFT073**waaL**, 1177**waaL** and RS218**waaL** mutants were all highly sensitive to human serum and displayed a high serum sensitivity index (SSI; \(P<0.05\), paired t-test). This phenotype reverted back to WT (i.e. resistant) in each of the respective complemented strains. The contribution of the capsule to serum resistance was less clear. The CFT073**kpsD** mutant was most sensitive (SSI = 2, \(P=0.046\)), while RS218**kpsD** displayed reduced sensitivity (SSI = 1, \(P=0.027\)). Complementation of the **kpsD** mutation in CFT073**kpsD** and RS218**kpsD** resulted in reversion to a WT resistance phenotype. The 1177**kpsD** mutant, on the other hand, was completely resistant.
Role of Capsule and O Antigen in UPEC Virulence

The E. coli K12 strain MG1655 was used as a control for the integrity of serum, and was completely killed in all assays. All the strains were resistant to heat-inactivated normal human sera (data not shown). Taken together, our data show that O antigen is the major determinant of serum resistance in the UPEC strains tested. Furthermore, given that 1177 and RS218 are K1 capsule type, the observed difference in their serum sensitivities indicate that the contribution of the capsule to serum resistance is closely linked to O antigen serotype.

UPEC survival in whole blood

The most well-characterized virulence-related role of capsular expression in UPEC relates to bacterial resistance to uptake and killing by phagocytes such as neutrophils and monocytes [15]. In view of this, and the data from the above assays that showed a less clear contribution of the capsule to serum resistance compared to O antigen, we performed a series of whole blood killing assays. In these experiments, the CFT073 \( \text{kpsD} \) and 1177 \( \text{kpsD} \) mutants displayed significantly enhanced sensitivity to killing by whole blood compared to their respective WT counterparts (Figure 5; \( P<0.05 \), independent samples t test); in contrast, RS218 WT was so sensitive to killing in this assay that the data on the \( \text{kpsD} \) mutants could not be interpreted. Complementation of the \( \text{kpsD} \) mutation in CFT073 \( \text{kpsD} \) and 1177 \( \text{kpsD} \) restored survival to WT levels. Given that 1177 and RS218 both produce a K1 capsule, these data suggest that there may be differences in the composition of their K1 antigen, or that the role of the K1 capsule in resistance to killing by whole blood is strongly linked to O antigen type, as observed in serum killing assays.

The O6 antigen and K2 capsule are required for colonization of the mouse urinary tract

Analysis of plasmid-based complemented strains in vivo is challenging as it is difficult to ensure consistent expression of the cloned gene or maintenance of the plasmid in the pathogen during infection. A major advantage of the counter selection strategy described here is that complementation is performed by repair of the mutated chromosomal gene, and thus the complemented strains can be tested in vivo. In order to demonstrate this, we analyzed the CFT073 WT, capsule and O antigen mutant and complemented strains in a mouse UTI model. Experiments were performed as mixed competition assays, whereby mice were inoculated with a 1:1 mix of CFT073:CFT073 \( \text{kpsD} \), CFT073\( \text{kpsD} \):CFT073\( \text{kpsD} \), CFT073\( \text{kpsD} \), CFT073\( \text{kpsD} \), and the number of colonizing bacteria was calculated at 18 h post infection. In these assays, both the capsule and O antigen mutants were significantly outcompeted by the WT and complemented strains in colonization of the bladder (Figure 6; \( P<0.05 \)). No significant colonization of the kidneys was observed (data not shown); this is consistent with previous data from our laboratory using C57BL/6 mice [38–41]. Taken together, these data demonstrate that the O6 antigen has a major impact on the colonization of the urinary tract by CFT073, and that the K2 capsular antigen, while less important, also contributes to this phenotype.
The polysaccharide capsule and O antigen are well-described UPEC virulence determinants that contribute to resistance against host defenses. Specific O and K types are associated with UPEC infection, often to different degrees depending on the serotype of the strain. In this study, we investigated the role of different O and K antigens in mediating resistance to serum and whole blood, and colonization of the urinary tract, using a novel set of WT, mutant and complemented strains.

Gene disruption in bacteria using λ-Red mediated homologous recombination is a widely used and highly efficient technique [42]. In this method, the mutation of a gene or set of genes is attained by insertional inactivation using an antibiotic cassette that can subsequently be removed by FLP-mediated recombination to leave a characteristic scar sequence at the target site. Several modifications have been made to λ-Red recombineering to improve recombination frequency that can otherwise be a major limitation in certain applications. These include using transformation amplifiers with large flanking regions [43], the removal of endogenous nucleases from the host strain [44], and the use of three-way overlapping PCR methods that negate the need for multiple intermediary cloning steps [45,46]. Complementation of a specific mutation, a common procedure used to prove the function of a gene and fulfill Koch’s postulates, is normally achieved in trans by introduction of the relevant gene into the cell on a plasmid. This approach, while effective, can be complicated by the need for antibiotic selection to maintain the plasmid [47,48], differences in copy number of the complemented gene due to its location on a plasmid [49] and differences in expression of the complemented gene [50]. These issues are often compounded when complementation is attempted in an animal infection model. Another approach for complementation involves the use of a transducing phage to repair the mutation on the chromosome [51]. This involves the replacement of up to 40 kb of the chromosomal region surrounding the target gene, and also requires the use of a strain-specific phage. A different allelic exchange strategy using suicide vectors can be employed when several rounds of modification are required, however problems such as the need for large flanking regions to facilitate recombination, loss of temperature sensitivity of the vector or drastically reduced recombination efficiency due to mismatched bases with target DNA sequences make this method less than ideal when dealing with non genome-sequenced clinical isolates [52]. Transposable elements also provide an alternative to λ-Red

Figure 2. Phenotypic characterization of capsule mutants (kpsD) and complemented (kpsD+) UPEC strains. A) Agar slab showing K1 phage reactions of 1177 and RS218 strains with CFT073 (expressing K2 antigen) as negative control; dashed lined through the center denotes line of phage suspension. Wild-type and complemented strains expressing K1 antigen are lysed by the phage and exhibit inhibited growth upon crossing the line of phage suspension. Growth of capsule mutants and the negative control strain is unaffected. B) Agarose gel showing precipitin bands arising from cross-linking of K2 antigen and antisera post electrophoresis. CFT073 WT and capsule complement show a positive reaction; no band is observed for the kpsD mutant due to loss of surface expression of the K2 antigen. doi:10.1371/journal.pone.0094786.g002

Figure 3. Analysis of lipopolysaccharide profiles by silver staining. Silver stained LPS profiles from strains listed below the gels. LPS banding patterns vary according to serotype; CFT073:O6 (A), E. coli 1177:O1 (B), RS218:O18 (C). Wild-type, O antigen mutant (waaL) and its complemented strain (waaL+) are ordered from left to right. The thick band at the bottom represents the lipid A core and is intact in all the strains. The bands stacked on top of the core represent different O antigen side chains of different lengths that disappear in the waaL mutant strains. Banding patterns are restored in the complemented strains and appear to be the same as the WT. doi:10.1371/journal.pone.0094786.g003
mediated homologous recombination. Transposition based strategies involving transposons such as Tn-5 and Tn-7, as well as their derivatives, have been used successfully to generate transposon mutant libraries [53,54] for site specific tagging [55] and for the generation of transcriptional/translational target gene fusions [56].

The \textit{rpsL} counter selection system has been used previously for the modification of bacterial artificial chromosomes in viral and eukaryotic systems [57-59]. In \textit{E. coli}, this system has been used in conjunction with \textit{loxP} to generate markerless chromosomal deletions [60] and to introduce point mutations at specific sites on the chromosome [36]. Here, we have demonstrated its application in the construction of mutant and complemented UPEC strains. The method for complementation was highly efficient, and only required the use of a 100 base oligonucleotide that matched the target region. Since the complementation method stably generates the parental genotype without the need for a selectable marker, complemented strains can be used in animal infection experiments without antibiotic selection. This method is analogous to that previously described for \textit{SacB}, another widely used counter selectable marker [61]. However, an advantage of \textit{rpsL} counter selection is that unlike the \textit{SacB} system, it can still be used in strains containing a native ColE1 replicon.

**Figure 4.** UPEC survival in human serum. Bacteria (approximately $4 \times 10^8$ CFU/ml) were incubated in fresh human serum for 90 min and colony counts were used to determine serum sensitivity index (SSI) for each strain, shown at the top of the graph. SSI of 0 represents a resistant strain; 1,2,3,4,5 represent equivalent reduction in log values of colony forming units (CFU/ml) post incubation with serum. The WT strains CFT073, 1177 and RS218 were resistant; CFT073\textit{waaL}, 1177\textit{waaL} and RS218\textit{waaL} mutants were all highly sensitive to human serum (SSI; $P<0.05$, paired t test) and the complemented strains (\textit{waaL}$^C$) were resistant. CFT073\textit{kspsD} and RS218\textit{kspsD} mutants displayed reduced sensitivity (SSI = 2 and 1, respectively); complemented strains (\textit{kspsD}$^C$) were resistant. The 1177\textit{kspsD} mutant was completely resistant to serum killing.

doi:10.1371/journal.pone.0094786.g004

**Figure 5.** Survival of UPEC CFT073 (A) and 1177 (B) WT, mutant and complemented strains in whole blood killing assays. Bacteria were incubated in fresh whole blood for 3–5 h and colony counts were used to compare survival phenotypes of mutants and complemented strains to the WT parents. Fitness of the CFT073 and 1177 capsule (\textit{kspsD}) mutants was significantly impaired compared to the WT, and was restored completely in the respective capsule complemented (\textit{kspsD}$^C$) strains. The survival data for the RS218 WT derivatives could not be analyzed due to the high sensitivity of WT strain to killing by whole blood. $P$ values, as determined by the independent samples, t test were as follows: \# 0.038, * 0.042.

doi:10.1371/journal.pone.0094786.g005
as well as mutants and repaired/complemented strains generated from these Strept derivatives. Although we did observe a slight decrease in exponential growth rate for the Strept derivatives, several of our mutants (which were Strept) still exhibited clear phenotypes with respect to serum resistance, whole blood killing and bladder colonization. Furthermore, our spontaneous CFT073 Strept derivative (CFT0073Strep) colonized the C57BL/6 mouse bladder at a similar level to that we have reported previously for CFT073 [38,68].

Three UPEC strains with different O and K antigens were used to demonstrate the application of the waaL counter selection system. For UPEC, the potential influence of waaL deletion and disruption of expression of O antigen on virulence is undefined except for a recent study that showed waaL was required for efficient colonization of mouse bladder [14]. Disruption of the waaL gene has been shown to result in uncapped lipid A-core due to the absence of a functional O antigen ligase [23,69]. Our waaL mutants had a similar lipid A-core region, while the characteristic O antigen was absent (and restored in complemented strains). The role of O antigen in mediating serum resistance in multiple bacterial pathogens has been extensively reported in the literature [32,43,70,71]. Our results demonstrate that the O1, O6 and O18 antigens are important for survival in serum. This is consistent with previous studies on the O18 antigen, which has been extensively studied in the context of neonatal meningitis strains [72–74]. Our results for the O1 and O6 antigens, while expected, represent to the best of our knowledge the first demonstration of this phenotype in well-defined mutant and complemented strains.

Mutation of the kpsD gene resulted in mutants lacking any surface exposed K antigen, and this was restored by complementation. In our experiments, the K2 capsule contributed to the resistance of CFT073 against the bactericidal activity of human serum. A study by Buckles et al. has shown the importance of the K2 capsule in UTI pathogenesis and its role in preventing complement mediated killing [31]. Notably, the serum sensitivity index for the K2 mutant in our study was significantly lower than its corresponding O antigen mutant (P<0.01). However, both of the strains were resistant to heat-inactivated normal human sera indicating a role for complement attack that depends at least in part, on the presence of O antigen. There are conflicting reports in the literature about the importance of K1 capsule in effecting bacterial survival in serum. A study by Leying et al. has suggested that K1 expression is a prerequisite for serum resistance [29]. However, the mutants used were not defined and complementation was not described. Likewise, Kim et al. reported that the K1 capsule plays a more important role than the O18 antigen in establishing bacteremia in a neonatal rat meningitis model [29]. In contrast, an earlier report concluded that in a similar animal model, the K1 capsule, while important for establishing meningitis, had no effect on bacterial survival in serum [75]. Several other reports have corroborated these findings [30,76,77]. Both the RS218 and 1177 strains used in our study produce a K1 capsule. We observed that while the absence of the capsule renders RS218 slightly susceptible to the bactericidal activity of serum, it had no significant effect on 1177. We also analyzed UPEC survival in whole blood to elucidate the role of capsule in protecting against whole blood killing. Survival of the CFT073 and 1177 capsule mutants was significantly impaired, which is similar to the role of K5 capsule antigen that mediates resistance to phagocytosis in UPEC [15]. The RS218 WT strain exhibited a poor survival rate and its corresponding mutants could not be analyzed by this assay. Thus, the importance of the K1 capsule in mediating serum resistance and survival in whole blood is variable, and possibly linked to the O antigen type and other factors such as hemolysin.

[62,63]. A disadvantage of the ypsL counter selection system is that it requires the generation of a spontaneous streptomycin resistant derivative of the strain to be studied, and it cannot be applied directly to strains with an existing streptomycin resistance cassette [64,65]. Mutations in the native ypsL gene have also been shown to result in a fitness cost on E. coli growth, with the decline in bacterial fitness dependent on the type of ypsL mutation and the carbon source available in the medium [66,67]. Thus, this issue needs to be considered when comparing the virulence of knockout and complemented strains where one is Strept and the other is Strept.

In this study, we used spontaneously generated Strept derivatives of each parent strain (referred to as WT for simplicity).

Figure 6. Fitness of CFT073 capsule (kpsD) and O antigen (waaL) mutants during in vivo competition with CFT073 WT and corresponding complemented (kpsD, waaL) strains. C57B/L6 mice were infected transurethrally with a 1:1 mixture of CFT073 kpsD and CFT073 WT or CFT073 kpsD and CFT073 waaL and CFT073 WT or CFT073 waaL. (A) Each marker represents LOG10 total CFU recovered from each mouse per 0.1 g of bladder tissue. Lines connect data points for the same mouse, and horizontal bars represent median values. (B) Each marker represents the LOG10 competitive index calculated for each individual mouse; competitive indices are the ratio of the mutant 0.1 g of bladder tissue to that of WT or complemented strain. Dashed lines represent hypothetical competitive index of 1 (LOG101 = 0), which indicates no difference in fitness between the two strains. Horizontal bars represent group medians, and each competition group had 6 to 8 mice. All mutants were significantly outcompeted by CFT073 WT or their respective complemented strains for bladder colonization (P<0.05). The O6 antigen was significantly more important than the K2 capsular antigen for bladder colonization (P<0.05).

doi:10.1371/journal.pone.0094786.g006
A key advantage of the rpsL counter selection strategy is that mutants can be complemented and studied in vivo. To demonstrate this, the ability of the CFT073 capsule and O antigen mutant strains to cause disease in a mouse UTI model was analyzed. We observed that both the K2 and O6 mutants were outcompeted by the WT and the complemented strains in bladder colonization during mixed infection challenges. However, based on competitive index the O6 antigen was significantly more important for disease pathogenesis than the K2 capsule. These results confirm the importance of the O6 antigen and, to some extent, the K2 capsular antigen, as colonization factors of the mouse urinary tract. The results are also consistent with a recent report demonstrating that restoration of the O-antigen producing capacity of the E. coli K12 strain MG1655 was sufficient for it to kill Caenorhabditis elegans at rates comparable to other pathogenic bacteria [83]. The expression of O antigen and capsule on the bacterial surface can also affect the function of other virulence factors [84,85]. Differences in the role of other UPEC K capsular antigens during infection have also been described previously. For example, the K15 antigen is important for virulence but not for serum resistance in a neonatal mouse UTI model [86], while a protective role for O4 but not for the K54 antigen has been described during colonization of the mouse urinary tract [87]. The O antigen and capsule are well known virulence factors of UPEC, however the interplay between common O and K antigens remains to be assessed using defined mutant and complemented strains. Here we have described a strategy to make single gene mutants and their complements that can be analyzed in vitro and in vivo.

### Table 1. Bacterial strains used in this study

| Strain | Relevant Characteristics | Reference |
|--------|--------------------------|-----------|
| E. coli K12 strains | | |
| MG1655 | ORK- | [94] |
| MC1061hsdR | hsdR, mcrB, araD, 139,(araABCleu) 7679 , galU galK rpsL thi | [47,95] |
| UPEC WT strains | | |
| CFT073 | O6:K2 | [96] |
| E. coli 1177 | O1:K1 | [97] |
| RS218 | O18:K1 | [98] |
| Streptomycin resistant strains | | |
| CFT073 Strep<sup>a</sup> | CFT073rpsL, Strep<sup>a</sup> | This study |
| E. coli 1177 Strep<sup>a</sup> | E.coli 1177rpsL, Strep<sup>a</sup> | This study |
| RS218 Strep<sup>a</sup> | RS218rpsL, Strep<sup>a</sup> | This study |
| CFT073 strains | | |
| CFT073(pRedET) | CFT073rpsL (pRedET), Strep<sup>a</sup>, Tet<sup>b</sup> | This study |
| CFT073psD | CFT073psD::rpsl-neo, Kan<sup>b</sup> | This study |
| CFT073psD(pRedET) | CFT073psD::rpsl-neo(pRedET), Kan<sup>b</sup>, Tet<sup>b</sup> | This study |
| CFT073psD<sup>C</sup> | Re-constructed CFT073 from CFT073psD, Strep<sup>a</sup> | This study |
| CFT073waal | CFT073waal::rpsl-neo, Kan<sup>b</sup> | This study |
| CFT073waal(pRedET) | CFT073waal::rpsl-neo(pRedET), Kan<sup>b</sup>, Tet<sup>b</sup> | This study |
| CFT073waal<sup>C</sup> | Re-constructed CFT073 from CFT073waal, Strep<sup>a</sup> | This study |
| E. coli 1177 strains | | |
| 1177(pRedET) | 1177rpsl (pRedET), Strep<sup>a</sup>, Tet<sup>b</sup> | This study |
| 1177psD | 1177psD::rpsl-neo, Kan<sup>b</sup> | This study |
| 1177psD(pRedET) | 1177psD::rpsl-neo(pRedET), Kan<sup>b</sup>, Tet<sup>b</sup> | This study |
| 1177psD<sup>C</sup> | Re-constructed 1177 from 1177psD, Strep<sup>a</sup> | This study |
| 1177waal | 1177waal::rpsl-neo, Kan<sup>b</sup> | This study |
| 1177waal(pRedET) | 1177waal::rpsl-neo(pRedET), Kan<sup>b</sup>, Tet<sup>b</sup> | This study |
| 1177waal<sup>C</sup> | Re-constructed 1177 from 1177waal, Strep<sup>a</sup> | This study |
| RS218 strains | | |
| RS218(pRedET) | RS218rpsL (pRedET), Strep<sup>a</sup>, Tet<sup>b</sup> | This study |
| RS218psD | RS218psD::rpsl-neo, Kan<sup>b</sup> | This study |
| RS218psD(pRedET) | RS218psD::rpsl-neo(pRedET), Kan<sup>b</sup>, Tet<sup>b</sup> | This study |
| RS218psD<sup>C</sup> | Re-constructed RS218 from RS218psD, Strep<sup>a</sup> | This study |
| RS218waal | RS218waal::rpsl-neo, Kan<sup>b</sup> | This study |
| RS218waal(pRedET) | RS218waal::rpsl-neo(pRedET), Kan<sup>b</sup>, Tet<sup>b</sup> | This study |
| RS218waal<sup>C</sup> | Re-constructed RS218 from RS218waal, Strep<sup>a</sup> | This study |

[78], outer membrane proteins (OmpA, OmpC) [79,80] and plasmid-encoded virulence factors [TraT, Iss] [81,82].

A key advantage of the rpsL counter selection strategy is that mutants can be complemented and studied in vivo. To demonstrate this, the ability of the CFT073 capsule and O antigen mutant strains to cause disease in a mouse UTI model was analyzed. We observed that both the K2 and O6 mutants were outcompeted by the WT and the complemented strains in bladder colonization during mixed infection challenges. However, based on competitive index the O6 antigen was significantly more important for disease pathogenesis than the K2 capsule. These results confirm the importance of the O6 antigen and, to some extent, the K2 capsular antigen, as colonization factors of the mouse urinary tract. The results are also consistent with a recent report demonstrating that restoration of the O-antigen producing capacity of the E. coli K12 strain MG1655 was sufficient for it to kill Caenorhabditis elegans at rates comparable to other pathogenic bacteria [83]. The expression of O antigen and capsule on the bacterial surface can also affect the function of other virulence factors [84,85]. Differences in the role of other UPEC K capsular antigens during infection have also been described previously. For example, the K15 antigen is important for virulence but not for serum resistance in a neonatal mouse UTI model [86], while a protective role for O4 but not for the K54 antigen has been described during colonization of the mouse urinary tract [87].

The O antigen and capsule are well known virulence factors of UPEC, however the interplay between common O and K antigens remains to be assessed using defined mutant and complemented strains. Here we have described a strategy to make single gene mutants and their complements that can be analyzed in vitro and in vivo.

---

**References**

[94] 139, (araABCleu) 7679

[96] 1177rpsl, Strep<sup>a</sup> | This study |

[97] 1177psD::rpsl-neo, Kan<sup>b</sup> | This study |

[98] 1177waal::rpsl-neo, Kan<sup>b</sup> | This study |

[86] 1177waal::rpsl-neo(pRedET), Kan<sup>b</sup>, Tet<sup>b</sup> | This study |

[99] RS218waal::rpsl-neo, Kan<sup>b</sup> | This study |

[100] RS218waal::rpsl-neo(pRedET), Kan<sup>b</sup>, Tet<sup>b</sup> | This study |

[101] Re-constructed RS218 from RS218waal, Strep<sup>a</sup> | This study |

[102] doi:10.1371/journal.pone.0094786.t001
With the aid of mutant and complemented strain sets we have shown that the surface expression of the O1, O6 and O18 antigens and to a lesser extent, the K2 antigen, are important for bacterial survival in human serum. O1, O6, K1 and K2 antigens were all found to provide a survival advantage in the presence of whole blood. The O6 antigen was shown to be more important than the K2 antigen for colonization of the mouse bladder. The strategy described herein can be applied to study other virulence factors with complex functions and thus avoid the use of plasmid-based systems for complementation.

Materials and Methods

Ethical approval

This study was carried out in strict accordance with the recommendations in the Animal Care and Protection Act (Queensland, 2002) and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (7th edition, 2004). Approval for mouse infection studies was obtained from the University of Queensland Animal Ethics Committee (SCMB/471/09/NHMRC (NF)). Approvals for the collection of human blood for serum sensitivity and whole blood killing assays were obtained from the University of Queensland Medical Research Ethics Committee (2008001123) and the Griffith University Human Research Ethics Committee (MSC/18/10/HREC), respectively.

Bacterial strains and growth conditions

The UPEC strains used in this study are listed in Table 1. Wild-type clinical isolates and their derivatives were routinely cultured at 28°C or 37°C on solid or in liquid Luria-Bertani (LB) medium [88] supplemented with the appropriate antibiotics: streptomycin (Strep, 100 μg/mL), kanamycin (Kan, 50 μg/mL), tetracycline (Tet, 5 μg/mL). Streptomycin-resistant derivatives of UPEC strains CFT073, 1177 and RS218 were generated by sequential growth on increasing concentrations of streptomycin (10 μg/mL, 25 μg/mL, 50 μg/mL and 100 μg/mL).

DNA manipulations and genetic techniques

Oligonucleotides used in this study were sourced from Sigma-Aldrich (Australia). Plasmid pRedET and the tpsL-neo template were obtained from the Counter selection BAC modification kit (GeneBridges). Isolation of plasmid DNA was carried out using the QIAprep Spin Miniprep Kit (Qagen). All polymerase chain reactions were performed using Taq DNA polymerase (New England Biolabs) under standard conditions except for reactions requiring high fidelity, in which case Phusion DNA polymerase (Thermo Scientific) was used. DNA sequencing for mutant and complementation was performed using the Big Dye v3.1 kit (Applied Biosystems) at the Australian Equine Genetics Research Centre, University of Queensland.

Construction of capsule and O antigen insertion mutants

Primers were designed using Vector NTI Advance 10 software (Invitrogen). Due to the unavailability of the RS218 and uawL single stranded 100 base oligonucleotides comprising a sequence identical to the WT strain in the mutated region (bps:CTCAACGTCAACGTCTACG-CCTCCTTTATTACAGGCAGCCGAGCGTAAAATGATCG-TGACCGGAGATTGGCTGTTACTGGAATCTGCGGATCGG-GCCGGTCGAGT; uawL:GGCGCGTGCAACGATATGATGCTTCCACCTTTGTTACTAATTATATCGTAAAGATGATCGG-AAAGT). Screening primers were designed at least 70 bp upstream and downstream of the homology regions, respectively. Their sequences are as follows: kpsD screen F: GATGGTTCGTACAGGGTGTATC; kpsD screen R: CCGCGCTTGACGACAGATCGT; uawL screen F: CACAGGACGCTACATCTCC; uawL screen R: CTTCATACATTGCAGCGCG. Streptomycin resistant UPEC strains CFT073, 1177 and RS218 were transformed with pRedET by electroporation and selected in the presence of tetracycline. These strains were then grown at 28°C to an optical density at 600 nm (OD600 nm) of 0.3, induced with L-arabinose (0.5% v/v) for approximately 1 h to allow expression of the recombinase genes, and then electroporated with the tpsL-neo cassette bearing the 50 bp homology regions. Mutants that were streptomycin sensitive (StrepS) and kanamycin resistant (KanR) were identified and insertion of the tpsL-neo cassette within the kpsD and uawL genes, respectively, was confirmed by PCR and sequencing.

Complementation of capsule and O antigen insertion mutants

Plasmid pRedET was re-introduced into the CFT073, 1177, and RS218 uawL and kpsD mutants, respectively. To repair the uawL and kpsD mutations, these strains were prepared as described above and transformed with 2 μM single-stranded 100 base oligonucleotides comprising a sequence identical to the WT strain in the mutated region (bps:CTCAACGTCAACGTCTACG-CCTCCTTTATTACAGGCAGCCGAGCGTAAAATGATCG-TGACCGGAGATTGGCTGTTACTGGAATCTGCGGATCGG-GCCGGTCGAGT; uawL:GGCGCGTGCAACGATATGATGCTTCCACCTTTGTTACTAATTATATCGTAAAGATGATCGG-AAAGT). Repair of the specific uawL or kpsD mutation in StrepS colonies was confirmed by PCR screening and sequencing.

K1 phage assay

K1 phage plaque was sourced from the Statens Serum Institut (Denmark). The cross-brush method recommended by the manufacturer was used to determine the presence of K1 antigen [89]. Briefly, a vertical line of phage suspension was streaked across an agar plate and allowed to dry. Horizontal lines of overnight E. coli broth cultures were then streaked from left to right across the phage suspension and plates were incubated at 37°C for 12 h. Inhibited growth or complete killing of bacteria after crossing the phage suspension was deemed a positive reaction. A negative reaction, in the absence of K1, was characterized by normal bacterial growth across the entire bacterial streak. CFT073 WT strain with K2 capsule was used as a negative control for the assay.

Counter current immunoelectrophoresis

E. coli diagnostic K2 antisera (Statens Serum Institut, Denmark) was used to detect the presence of the K2 antigen. Capsule extracts were made according to manufacturer guidelines. Briefly, the bacterial cells from an agar plate were suspended in 1 ml phosphate buffered saline (PBS) (pH 7.4) and incubated at 60°C.
for 20 min. The cell suspension was then centrifuged for 30 min at 14,000 rpm and the supernatant transferred to a fresh tube and heated for 1 h at 95°C. Extracts were then diluted in PBS (1:50) for electrophoresis. A 1.5% agarose gel was applied to a glass plate with 2 rows of wells and a distance of 5 mm between each row. 15 μl of K2 antisera and diluted capsule extracts were loaded at the anode and cathode ends, respectively. Counter-current immunoelectrophoresis was performed for 70 min at 80 V in 1X TAE buffer. A precipitin band between the wells demonstrated the presence of a K2 capsule.

LPS isolation and silver staining

LPS was extracted as described previously by West et al. [90]. Tricine-SDS PAGE (TSDS PAGE) was used to obtain a high resolution of LPS. Gels were cast with a 16.5% resolving phase containing 4 M urea, overlaid with a 4% stacking phase. A two-buffer system was used for electrophoresis as previously described [91]. Electrophoresis was performed in the Mini-PROTEAN gel apparatus (BioRad) at 50 V for 30 min and then at 150 V for 70 min. A modified silver staining method originally described by Tsai and Frasch [92] was used to view LPS bands. Gels were transferred to a glass tray and fixed overnight (40% ethanol, 5% glacial acetic acid) at room temperature. The fixing solution was replaced with an oxidizing solution (40% ethanol, 5% glacial acetic acid, 0.7% periodic acid) and incubated for 7 min. Gels were washed repeatedly in copious amounts of milliQ water and then stained (20 mM sodium hydroxide, 0.4% ammonium hydroxide, 0.7% silver nitrate) for 10 min. The staining solution was removed and gels were incubated in the dark in a developing solution (0.02% formaldehyde, 0.26 mM citric acid) until distinct bands were visible. Gels were then washed in water to stop the reaction.

Serum killing assay

Overnight bacterial cultures were washed in PBS and then standardized to a final OD₆₀₀ = 0.8 (approximately 4×10⁸ CFU/ml). A volume of 50 μl of each standardized culture was mixed with an equal volume of PBS and serially diluted for colony counts on agar to enumerate CFU prior to serum treatment (t = 0 min). Fresh blood was collected in EDTA-free vacutainer tubes on the day of the assay from two healthy human donors who gave informed consent. The same donors were used for all assays in order to reduce serum variability. Blood was allowed to clot for 1 h at 95°C. Extracts were then diluted in PBS (1:50) and serially diluted for colony counts with an equal volume of PBS and plated onto streptomycin and kanamycin-containing LB agar for colony counts. The two strains in each group were differentiated by their resistance to kanamycin and kanamycin-containing LB agar for colony counts. The two strains in each group were differentiated by their resistance to kanamycin (WT) and complemented mutants. Significance was determined using the two-tailed Wilcoxon matched pairs test on CFU/ml urine, or CFU/0.1 g bladder tissue using Prism6 (GraphPad). P values <0.05 were considered significant.

Acknowledgments

We thank Barbara Arnts and Kendall Hepple for expert technical assistance with the mouse UTI model.

Author Contributions

Conceived and designed the experiments: SS GCU MT MDP MAS. Performed the experiments: SS GCU. Analyzed the data: SS GCU. Contributed reagents/materials/analysis tools: GCU MAS. Wrote the paper: SS GCU MT MDP MAS.

References

1. Stamm WE, Norbury SR (2001) Urinary tract infections: disease panorama and challenges. J Infect Dis 183 Suppl 1: S1–4.
2. Foxxon B (2002) Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. American Journal of Medicine 115: 58–68.
3. Chenoweth CE, Saint S (2011) Urinary tract infections. Infect Dis Clin North Am 25: 103–115.
4. Buonassisi D, Catarini L (2012) Urinary tract infections in children: a review. Minerva Pediatr 64: 143–157.
5. Nicolle LE (2001) Urinary tract infections in long-term-care facilities. Infect Control Hosp Epidemiol 22: 167–175.
6. Stamm WE, Hooton TM (1993) Management of Urinary-Tract Infections in Adults. New England Journal of Medicine 329: 1328–1334.
7. Hacker J, Bender L, Ott M, Wingender J, Lund B, et al. (1996) Deletions of chromosomal regions coding for fimbriae and hemolysins occur in vitro and in vivo in various extraintestinal Escherichia coli isolates. Microb Pathog 8: 213–225.
36. Heermann R, Zeppenfeld T, Jung K (2008) Simple generation of site-directed point mutations in the Escherichia coli chromosome using Red(R)/ET(R) method. J Bacteriol 190: 7016–7021.

37. Lederberg J (1951) Streptomycin resistance; a genetically recessive mutation. J Bacteriol 61: 549–550.

38. Ulett GC, Valle J, Belsio C, Sherlock O, Ghigo JM, et al. (2007) Functional analysis of antigen 43 in uropathogenic Escherichia coli reveals a role in long-term persistence. Infect Immun 75: 3233–3244.

39. Allopp LA, Tosiska M, Tree J, Ulett GC, Mahbub AN, et al. (2010) UplA is a newly identified autotransporter protein that contributes to biofilm formation and bladder colonization by uropathogenic Escherichia coli CFT073. Infect Immun 78: 5809–5818.

40. Duell BL, Carey AJ, Tan CK, Cui X, Webb RI, et al. (2012) Inmate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 to inhibit urinary tract infection. Infect Immun 79: 5056–5065.

41. Tan CK, Carey AJ, Cui X, Webb RI, Ipe D, et al. (2012) Genome-wide mapping of cytins due to Streptococcus agalactiae and Escherichia coli in mice identifies a unique bladder transcriptome that signifies pathogen-specific antimicrobial defense against urinary tract infection. Infect Immun 80: 3145–3160.

42. Daniseno KA, Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97: 6640–6645.

43. Plan MD, Peters KM, Sarkar S, Lukowski SW, Allopp LA, et al. (2013) The Serum Resistance of a Globally Disseminated Multidrug Resistant Uropathogenic Clonal Phage. Plas Genet 9: e1003534.

44. Mosteb JA, Gregg CJ, Laioje MJ, Wang HH, Church GM (2012) Improving lambda red DNA engineering in E. coli through rational removal of endogenous nucleases. PLoS One 7: e46638.

45. Webb JS, Nikolakakis KC, Willett JL, Aoki SK, Hayes CS, et al. (2015) Delivery of CdA nucleic toxins into target cells during contact-dependent growth inhibition. PLoS One 10: e0145761.

46. Derbie A, Leslie B, Dachaux D, Ghigo JM, Carmel E (2003) A rapid and simple method for inactivating chromosomal genes in Yersinia. FEMS Immunol Med Microbiol 38: 113–116.

47. Menninger PS, Sisk WP, Berman ML (1997) Bacteriophage lambda clone Drug Targets 13: 1306–1399.

48. Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. Annu Rev Immunol 20: 667–704.

49. Perez JM, McGarry MA, Marolda CL, Valvano MA (1999) Structural, assembly and regulation of expression of the K. pneumoniae K1 polysaccharide antigen genes. J Bacteriol 181: 6131–6138.

50. Howard CJ, Glynn AA (1971) Virulence for mice of strains of Escherichia coli carrying the capsular polysaccharide. J Bacteriol 105: 568–575.

51. Battaglioli EJ, Baisa GA, Weeks AE, Schroll RA, Hryckowian AJ, et al. (2011) Artificial chromosomes. Nat Methods 9: 103–109.

52. Lederberg J (1951) Streptomycin resistance; a genetically recessive mutation. J Bacteriol 61: 549–550.

53. Silver RP, Anderson MJ, Vann WF, Aaronson W (1984) Genetic and molecular analyses of the K2 Capsule in Escherichia coli Urinary Tract Infection and Serum Phenomenon. Apmis 98: 828–838.

54. Meissner PS, Vann WF, Berman ML (1997) Bacteriophage lambda clone Drug Targets 13: 1306–1399.

55. Lambertsen L, Sternberg C, Molin S (2004) Mini-Tn7 transposons for site-specific mutagenesis of a periplasmic protein. J Bacteriol 186: 3441–3448.

56. Balskus EP, Tschida RS, Toonen RL, Marston BJ, White JJ, et al. (2011) Inhibition of endogenous nucleases. PLoS One 7: e44638.

57. Bird AW, Erler A, Fu J, Heriche JK, Maresca M, et al. (2012) High-efficiency Cre/lox for generation of markerless chromosomal deletions in bacterial populations. Proc Natl Acad Sci U S A 109: 2191–2196.

58. Schwartz JA, Brittle EE, Reynolds AE, Enquist LW, Silverstein SJ (2006) UL54-1004 encodes a protein involved in transport of polysialic acid in Escherichia coli K1. J Bacteriol 188: 1148–1157.

59. Soussy CJ, Wolfson JS, Ng EY, Hooper DC (1993) Limitations of plasmid copy number in bacteria. PLoS One 5: e9328.

60. Siegelaub A, Ha JC (1997) Gene expression from plasmids containing the arabinose promoter at sub saturating inducer concentrations represents mixed populations. Proc Natl Acad Sci U S A 94: 8168–8172.

61. Berg RJ, Mancino ME, Mercurio MA, Barco TC, Apostolou M, et al. (2011) Bacteriophage lambda clone Drug Targets 13: 1306–1399.

62. Bartig J, Wollmann JS, Ng EY, Hooper DC (1993) Limitations of plasmid copy number in bacteria. PLoS One 5: e9328.

63. Watve MM, Dahanukar N, Watve MG (2010) Sociobiological control of plasmid copy number in bacteria. PLoS One 5: e9328.

64. Schwartz JA, Brittle EE, Reynolds AE, Enquist LW, Silverstein SJ (2006) UL54-1004 encodes a protein involved in transport of polysialic acid in Escherichia coli K1. J Bacteriol 188: 1148–1157.

65. Soussy CJ, Wolfson JS, Ng EY, Hooper DC (1993) Limitations of plasmid copy number in bacteria. PLoS One 5: e9328.

66. Siegelaub A, Ha JC (1997) Gene expression from plasmids containing the arabinose promoter at sub saturating inducer concentrations represents mixed populations. Proc Natl Acad Sci U S A 94: 8168–8172.

67. Battiglioni J, Baird GA, Weeks AE, Schroll RA, Hryckowian AJ, et al. (2011) Isolation of generalized transducing bacteriophages for uropathogenic strains of Escherichia coli. Appl Environ Microbiol 77: 6630–6633.

68. Emmerson JR, Gally DL, Roe AJ (2006) Generation of gene deletions and gene replacements in Escherichia coli O157: H7 using a temperature sensitive allelic exchange system. Biological Chemistry 273: 8449–8459.

69. Goryshin IY, Naumann TA, Apodaca J, Reinikoff WS (2003) Chromosomal deletion formation system based on Tn5 double translocation: use for making minimal genomes and essential gene analysis. Genome Res 13: 645–653.

70. Wang G, Musser JM, Lucek RP, Kaper JB, Schneewind O (2001) Whole-genome microarray analysis of Rabbit and Human-Neutrophils. Infect Immun 69: 1067–1077.

71. Meissner PS, Vann WF, Berman ML (1997) Bacteriophage lambda clone Drug Targets 13: 1306–1399.

72. Lederberg J (1951) Streptomycin resistance; a genetically recessive mutation. J Bacteriol 61: 549–550.

73. Silver RP, Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97: 6640–6645.

74. Soussy CJ, Wollfman JS, Ng EY, Hooper DC (1993) Limitations of plasmid copy number in bacteria. PLoS One 5: e9328.

75. Siegelaub A, Ha JC (1997) Gene expression from plasmids containing the arabinose promoter at sub saturating inducer concentrations represents mixed populations. Proc Natl Acad Sci U S A 94: 8168–8172.

76. Bartig J, Wollfman JS, Ng EY, Hooper DC (1993) Limitations of plasmid copy number in bacteria. PLoS One 5: e9328.

77. Battiglioni J, Baird GA, Weeks AE, Schroll RA, Hryckowian AJ, et al. (2011) Isolation of generalized transducing bacteriophages for uropathogenic strains of Escherichia coli. Appl Environ Microbiol 77: 6630–6633.

78. Emmerson JR, Gally DL, Roe AJ (2006) Generation of gene deletions and gene replacements in Escherichia coli O157: H7 using a temperature sensitive allelic exchange system. Biological Chemistry 273: 8449–8459.

79. Goryshin IY, Naumann TA, Apodaca J, Reinikoff WS (2003) Chromosomal deletion formation system based on Tn5 double translocation: use for making minimal genomes and essential gene analysis. Genome Res 13: 645–653.

80. Wang G, Musser JM, Lucek RP, Kaper JB, Schneewind O (2001) Whole-genome microarray analysis of Rabbit and Human-Neutrophils. Infect Immun 69: 1067–1077.

81. Meissner PS, Vann WF, Berman ML (1997) Bacteriophage lambda clone Drug Targets 13: 1306–1399.
64. Sandvang D (1999) Novel streptomycin and spectinomycin resistance gene as a gene cassette within a class 1 integron isolated from Escherichia coli. Antimicrob Agents Chemother 43: 3036–3038.

65. Hollingshead S, Vangue D (1985) Nucleotide sequence analysis of a gene encoding a diol dehydrase in the spectinomycin adenyltransferase. Plasmid 13: 17–30.

66. Paulander W, Malmier-Patino S, Andersson DI (2009) The fitness cost of streptomycin resistance depends on rpsL mutation, carbon source and RpsL (sigmaS). Genetics 183: 539–546, 531SL–532SL.

67. Enne VI, Delsol AA, Davis GR, Hayward SL, Roe JM, et al. (2005) Assessment of the fitness impacts on Escherichia coli of acquisition of antibiotic resistance genes encoded by different types of genetic element. J Antimicrob Chemother 56: 544–551.

68. DeShazer D, Brent PJ, Woods DE (1998) The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol Microbiol 30: 1081–1100.

69. Bravo D, Silva C, Carter JA, Hoare A, Alvarez SA, et al. (2008) Growth-phase interaction of outer membrane protein A with C4b binding protein mediates killing of human blood granulocytes. Inhibition by alpha-hemolysin. J Bacteriol 190: 6099–6112.

70. Enne VI, Delsol AA, Davis GR, Hayward SL, Roe JM, et al. (2005) Assessment of the fitness impacts on Escherichia coli of acquisition of antibiotic resistance genes encoded by different types of genetic element. J Antimicrob Chemother 56: 544–551.

71. Taylor PW (1976) Immunochemical investigations on lipopolysaccharides and lipooligosaccharides. J Bacteriol 127: 939–946.

72. Pluschke G, Mayden J, Achtman M, Levine RP (1983) Role of the capsule and O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing. Infect Immun 42: 907–913.

73. Hughes C, Phillips R, Roberts AP (1982) Serum resistance among Escherichia coli strains causing urinary tract infection in relation to O type and the carriage of hemolysin, colicin, and antibiotic resistance determinants. Infect Immun 35: 270–273.

74. Cohen MJ, Cross AS, Saedou JC, Fair E (1990) Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines. Infect Immun 58: 373–377.

75. Bortolussi R, Ferrieri P, Bjorksten B, Quie PG (1979) Capsular K1-Polysaccharide of Escherichia-Coli - Relationship to Virulence in Newborn Rats and Resistance to Phagocytosis. J Infect Dis 139: 293–298.

76. McCabe WR, Kaijser B, Olling S, Uwaydah M, Hanson LA (1978) Escherichia coli strains causing urinary tract infection in relation to O type and the carriage of hemolysin, colicin, and antibiotic resistance determinants. Infect Immun 35: 270–273.

77. Pluschke G, Mayden J, Achtman M, Levine RP (1983) Role of the capsule and O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing. Infect Immun 42: 907–913.

78. Bertani G (1951) Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli. J Bacteriol 62: 293–300.

79. Orosz F, Orosz L (1984) Swarming of Escherichia coli. J Bacteriol 158: 544–551.

80. Liu YF, Yan JJ, Lei HY, Teng CH, Wang MC, et al. (2012) Loss of outer membrane protein C in Escherichia coli contributes to both antibiotic resistance and escaping antibody-dependent bactericidal activity. Infect Immun 80: 1815–1822.

81. Montenegro MA, Bitter-Suemann D, Timmis JK, Aguerro ME, Cabell PC, et al. (1983) traT gene sequences, serum resistance and pathogenicity-related factors in clinical isolates of Escherichia coli and other gram-negative bacteria. J Gen Microbiol 131: 1511–1521.

82. Binns MM, Mayden J, Levine RP (1982) Further characterization of complement resistance conferred on Escherichia coli by the plasmid genes traT of R100 and is of CoIV.KK4. Infect Immun 35: 654–659.

83. Brownling DF, Wells TJ, Franca FL, Morris GC, Sevastyanovich YR, et al. (2013) Laboratory adapted Escherichia coli K-12 becomes a pathogen of Caenorhabditis elegans upon restoration of O antigen biosynthesis. Mol Microbiol 87: 939–950.

84. Schembri MA, Dalgaard D, Klemm P (2004) Capsule shields the function of short bacterial adhesins. J Bacteriol 186: 1249–1257.

85. Schembri MA, Blom J, Kroghet KA, Klemm P (2005) Capsule and fimbra interaction in Klebsiella pneumoniae. Infect Immun 73: 4626–4633.

86. Schneider G, Dobrindt U, Bruggmann H, Nagy G, Janke B, et al. (2004) The pathogenicity island-associated K15 capsule determinant exhibits a novel genetic structure and correlates with virulence in uropathogenic Escherichia coli strain 536. Infect Immun 72: 5993–6001.

87. Russo TA, Brown JJ, Jedush ST, Johnson JR (1996) The O4 specific antigen moiety of lipopolysaccharide but not the K54 group 2 capsule is important for virulence of an extraintestinal isolate of Escherichia coli. Infect Immun 64: 2343–2348.

88. Svanborg Eden C, Gotschlich EC, Korhonen TK, Leffler H, Schoolnik G (1983) O antigen in resistance of O18:K1 Escherichia coli to complement-mediated killing. Infect Immun 42: 907–913.

89. Lesse AJ, Fattah SA, Klemm P, Cabello FC, Aguero ME (2005) Characterization of a novel outer membrane protein (OmpC) in uropathogenic Escherichia coli strain 83972. J Gen Microbiol 151: 1811–1819.

90. Lesse AJ, Fattah SA, Klemm P, Cabello FC, Aguero ME (2005) Characterization of a novel outer membrane protein (OmpC) in uropathogenic Escherichia coli strain 83972. J Gen Microbiol 151: 1811–1819.

91. Lesse AJ, Campagnari AA, Bittner WE, Apicella MA (1990) Increased susceptibility of Escherichia coli to phagocytosis and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect Immun 58: 4673–4680.

92. Rats and Resistance to Phagocytosis. Infect Immun 25: 293–298.

93. In vitro cytotoxic effect of alpha-hemolytic streptococci. Journal of Immunol 169: 6352–6360.

94. Resolution of Lipopolysaccharides and Lipooligosaccharides Utilizing Tricine-Sodium Dodecyl Sulfate-Polyacrylamide Gel-Electrophoresis. Journal of Immunological Methods 126: 109–112.

95. In vitro cytotoxic effect of alpha-hemolytic streptococci. Journal of Immunol 169: 6352–6360.

96. In vitro cytotoxic effect of alpha-hemolytic streptococci. Journal of Immunol 169: 6352–6360.

97. In vitro cytotoxic effect of alpha-hemolytic streptococci. Journal of Immunol 169: 6352–6360.

98. In vitro cytotoxic effect of alpha-hemolytic streptococci. Journal of Immunol 169: 6352–6360.

99. In vitro cytotoxic effect of alpha-hemolytic streptococci. Journal of Immunol 169: 6352–6360.

100. In vitro cytotoxic effect of alpha-hemolytic streptococci. Journal of Immunol 169: 6352–6360.